CA1268208A - Micro-particules magnetiques servant d'agents de contraste en imagerie a resonance magnetique nucleaire - Google Patents
Micro-particules magnetiques servant d'agents de contraste en imagerie a resonance magnetique nucleaireInfo
- Publication number
- CA1268208A CA1268208A CA000485587A CA485587A CA1268208A CA 1268208 A CA1268208 A CA 1268208A CA 000485587 A CA000485587 A CA 000485587A CA 485587 A CA485587 A CA 485587A CA 1268208 A CA1268208 A CA 1268208A
- Authority
- CA
- Canada
- Prior art keywords
- tissue
- magnetic
- micro
- particles
- image
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 56
- 239000011859 microparticle Substances 0.000 title claims abstract description 38
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 title claims description 5
- 239000002872 contrast media Substances 0.000 title description 11
- 239000000696 magnetic material Substances 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 19
- 230000027455 binding Effects 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 239000005556 hormone Substances 0.000 claims description 9
- 229940088597 hormone Drugs 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 239000003302 ferromagnetic material Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000193 iodinated contrast media Substances 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005307 ferromagnetism Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007717 redox polymerization reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64003784A | 1984-08-10 | 1984-08-10 | |
| US640,037 | 1984-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1268208A true CA1268208A (fr) | 1990-04-24 |
Family
ID=24566571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000485587A Expired CA1268208A (fr) | 1984-08-10 | 1985-06-27 | Micro-particules magnetiques servant d'agents de contraste en imagerie a resonance magnetique nucleaire |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA1268208A (fr) |
| DE (1) | DE3590398T1 (fr) |
| GB (1) | GB2177199A (fr) |
| WO (1) | WO1986001112A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223242A (en) * | 1985-11-05 | 1993-06-29 | The General Hospital Corporation | Negatively charged specific affinity reagents |
| JPS62181229A (ja) * | 1985-11-05 | 1987-08-08 | ザ・ゼネラル・ホスピタル・コ−ポレ−シヨン | 負に荷電した特異親和性試薬 |
| US5055288A (en) * | 1987-06-26 | 1991-10-08 | Advanced Magnetics, Inc. | Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides |
| US5314679A (en) * | 1986-07-03 | 1994-05-24 | Advanced Magnetics Inc. | Vascular magnetic resonance imaging agent comprising nanoparticles |
| FR2612400A1 (fr) * | 1987-03-16 | 1988-09-23 | Centre Nat Rech Scient | Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale |
| DE3709851A1 (de) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
| US5314681A (en) * | 1988-12-23 | 1994-05-24 | Nycomed Innovation Ab | Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging |
| US5164297A (en) * | 1990-05-03 | 1992-11-17 | Advanced Magnetics Inc. | Solvent mediated relaxation assay system |
| US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| GB9020075D0 (en) * | 1990-09-14 | 1990-10-24 | Filler Aaron G | Contrast agents for magnetic resonance imaging of axonal transport |
| WO1992004916A2 (fr) * | 1990-09-14 | 1992-04-02 | St. George's Enterprises Limited | Agents sous forme de particules |
| US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
| DE4309333A1 (de) * | 1993-03-17 | 1994-09-22 | Silica Gel Gmbh | Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben |
| EP0800545B2 (fr) * | 1995-11-01 | 2011-03-02 | Bracco Research S.A. | Systemes de marqueur moleculaire cible, a etiquetage magnetique, pour imagerie a resonance magnetique nucleaire |
| GB9600427D0 (en) * | 1996-01-10 | 1996-03-13 | Nycomed Imaging As | Contrast media |
| EP0877630B1 (fr) | 1996-01-10 | 2005-03-23 | Amersham Health AS | Milieu de contraste |
| US8669236B2 (en) | 2005-05-12 | 2014-03-11 | The General Hospital Corporation | Biotinylated compositions |
| CA2883130A1 (fr) | 2012-08-31 | 2014-03-06 | The General Hospital Corporation | Complexes de biotine pour le traitement et le diagnostic de la maladie d'alzheimer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3129906C3 (de) * | 1981-07-24 | 1996-12-19 | Schering Ag | Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik |
| US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
-
1985
- 1985-06-27 CA CA000485587A patent/CA1268208A/fr not_active Expired
- 1985-08-06 WO PCT/US1985/001495 patent/WO1986001112A1/fr not_active Ceased
- 1985-08-06 DE DE19853590398 patent/DE3590398T1/de not_active Withdrawn
- 1985-08-06 GB GB08607629A patent/GB2177199A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE3590398T1 (de) | 1986-08-28 |
| WO1986001112A1 (fr) | 1986-02-27 |
| GB8607629D0 (en) | 1986-04-30 |
| GB2177199A (en) | 1987-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4863715A (en) | Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material | |
| Renshaw et al. | Ferromagnetic contrast agents: a new approach | |
| US5069216A (en) | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract | |
| US4827945A (en) | Biologically degradable superparamagnetic materials for use in clinical applications | |
| US4951675A (en) | Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging | |
| WO1986001112A1 (fr) | Les microparticules comme agents de contraste dans la production d'images par resonance magnetique nucleaire | |
| AU652829B2 (en) | Melanin-based agents for image enhancement | |
| US4770183A (en) | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents | |
| Groman et al. | Ultrasmall mixed ferrite colloids as multidimensional magnetic resonance imaging, cell labeling, and cell sorting agents | |
| Renshaw et al. | Immunospecific NMR contrast agents | |
| Widder et al. | Magnetite albumin microspheres: a new MR contrast material | |
| US5219554A (en) | Hydrated biodegradable superparamagnetic metal oxides | |
| Glazer | MR imaging of the liver, kidneys, and adrenal glands. | |
| Zhu et al. | Fluorescent magnetic Fe3O4/rare earth colloidal nanoparticles for dual‐modality imaging | |
| JPH07110815B2 (ja) | 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤 | |
| US5458870A (en) | Compositions for magnetic resonance imaging using a manganese oxalate | |
| Zhong et al. | A rheumatoid arthritis magnetic resonance imaging contrast agent based on folic acid conjugated PEG-b-PAA@ SPION | |
| Galperin et al. | Synthesis and characterization of radiopaque magnetic core‐shell nanoparticles for X‐ray imaging applications | |
| Lahooti et al. | Preliminary studies of 68Ga-NODA-USPION-BBN as a dual-modality contrast agent for use in positron emission tomography/magnetic resonance imaging | |
| JP5350257B2 (ja) | 免疫磁気ｍｒｉ造影剤を用いた活性化された血管内皮の画像化 | |
| JPH10509424A (ja) | 磁気共鳴イメージングで顕著な効果を示すキレート錯体 | |
| CN102935241B (zh) | 一种用于诊断乳腺癌的mri对比剂及其制备方法 | |
| CHOI et al. | Necrotic areas in VX2 carcinoma of rabbits: correlation of magnetic resonance imaging and pathologic appearance | |
| Yan et al. | Dextran gadolinium complexes as contrast agents for magnetic resonance imaging to sentinel lymph nodes | |
| CA2271735C (fr) | Agents d'imagerie du pool sanguin par resonance magnetique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |